This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 35
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=64825282&loc=d3e32787-111569

+ Details

Name:	us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Other (Income)/Deductions - Net - Footnotes - Indefinite-Lived Intangibles (Details) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Dec. 31, 2016	Jul. 03, 2016	Apr. 03, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				$ 869	$ 323	$ 396
Operating Segments [Member] \| Essential Health Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				840	294	166
Operating Segments [Member] \| Innovative Health Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				29		12
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments					71	190
In Process Research and Development [Member] \| Hospira [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				265
In Process Research and Development [Member] \| InnoPharma [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				128
Other In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				110
Other In Process Research and Development [Member] \| Hospira [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				81
Other In Process Research and Development [Member] \| King [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				29
Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments					132
Trade Names [Member] \| Xanax/Xanax XR [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments						47
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Indefinite-lived Intangible Assets [Line Items]
Equity method investment, other than temporary impairment	$ 241	$ 130	$ 81	$ 452	$ 463
Equity method investment, ownership percentage	49.00%			49.00%	49.00%
Laboratorio Teuto Brasilero [Member]
Indefinite-lived Intangible Assets [Line Items]
Equity method investment, other than temporary impairment				$ 50		56
Equity method investment, ownership percentage	40.00%			40.00%
Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments						159
Developed Technology Rights [Member] \| Hospira [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments				$ 366
Pfizer's Worldwide Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments					$ 13	190
Consumer Healthcare [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairments					$ 17	$ 28